Fibrinolytic and Haemostatic Responses to Desamino-D-Arginine Vasopressin (DDAVP) Administered by Intravenous and Subcutaneous Routes in Healthy Subjects

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Thrombosis and Haemostasis

• Publication date

  1988-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0038-1642561PMID 3129807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on the Procurement of Blood Coagulation Factor VIII

  1988cited by this paper
• Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization.

  1987cited by this paper
• Immunoaffinity Purification of Factor VIII Complex

  1987cited by this paper
• Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

  1986cited by this paper
• The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII

  1986cited by this paper
• Room Temperature, Microtray Chromogenic Assay of Factor VIII:C

  1986cited by this paper
• Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)

  1986cited by this paper
• Desmopressin (DDAVP) for treatment of disorders of hemostasis.

  1986cited by this paper
• Desmopressin.

  1985cited by this paper
• Comparison Between Subcutaneous and Intravenous DDAVP in Mild and Moderate Hemophilia A

  1985cited by this paper
• Fibrinolytic shut‐down after surgery: impairment of the balance between tissue‐type plasminogen activator and its specific inhibitor

  1985cited by this paper
• Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.

  1985cited by this paper
• A Collaborative Study of a Proposed International Standard for Tissue Plasminogen Activator (t-PA)

  1985cited by this paper
• Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma

  1984cited by this paper
• A Comparative Study Using Immunological and Biological Assays of the Haemostatic Responses to DDAVP Infusion Venous Occlusion and Exercise in Normal Men

  1984cited by this paper
• Tissue plasminogen activator in human plasma measured by radioimmunoassay.

  1983cited by this paper
• Monoclonal antibodies to human procoagulant factor VIII.

  1983cited by this paper
• Plasminogen activator release during venous stasis and exercise as determined by a new specific assay.

  1983cited by this paper
• Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue

  1982cited by this paper
• The Use of Desmopressin Acetate (DDAVP) as a Test of the Fibrinolytic Capacity of Patients – Analysis of Responders and Non-Responders

  1982cited by this paper
• Factor VIII and Fibrinolytic Response to Deamino‐8‐d‐Argenine Vasopressin in Normal Subjects and Dissociate Response in Some Patients with Haemophilia and von Willebrand's Disease

  1980cited by this paper
• Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.

  1980cited by this paper
• 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

  1977cited by this paper
• Electroimmuno assay.

  1972cited by this paper
• Determination of serum proteins by means of the biuret reaction.

  1949cited by this paper

• Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review.

  2022cites this paper
• Transfusion Medicine and Coagulation Disorders

  2017cites this paper
• Endothelial Cell Processing and Alternatively Spliced Transcripts of Factor VIII: Potential Implications for Coagulation Cascades and Pulmonary Hypertension

  2010cites this paper
• Die Wirkung von niedrig dosiertem Desmopressin auf die durch Acetylsalicylsäure verlängerte Blutungszeit

  2010cites this paper
• The Effectiveness of Prophylactic Desmopressin in Coronary Artery Surgery

  2008cites this paper
• Guideline for the treatment of haemophilia in South Africa.

  2008cites this paper
• Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood

  2005cites this paper
• Effects of desmopressin on thrombogenesis in aspirin‐induced platelet dysfunction

  2002cites this paper
• Desmopressin usage in elective cardiac surgery.

  2001cites this paper
• Effects of deamino-8-D-arginin vasopressin on blood loss and coagulation factors in scoliosis surgery. A double-blind randomized clinical trial.

  1999cites this paper
• Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery.

  1999cites this paper
• Variability of the factor VIII response to DDAVP in a large kindred with mild haemophilia A

  1997cites this paper
• Hemostatic and fibrinolytic response to desmopressin in uremic patients.

  1997cites this paper
• Hemostatic Drugs in Prothrombotic or Hypercoagulable States

  1997cites this paper
• Effect of a 15-Minute Infusion of DDAVP on the Pharmacokinetics and Pharmacodynamics of ™REVASC during a Four-Hour Intravenous Infusion in Healthy Male Volunteers

  1997cites this paper
• DDAVP Reduces Bleeding during Continued Hirudin Administration in the Rabbit

  1996cites this paper
• A mathematical model of coagulation factor VIII kinetics.

  1996cites this paper
• The Role of DDAVP (Desmopressin) in Orthognathic Surgery

  1996cites this paper
• Randomized Study of Aprotinin and DDAVP to Reduce Postoperative Bleeding After Cardiopulmonary Bypass Surgery

  1994cites this paper
• Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin.

  1993cites this paper
• Desmopressin and hemostasis.

  1993cites this paper
• Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia

  1993cites this paper
• Therapy of Factor VIII Deficiency

  1993cites this paper
• Fibrinolytic Behaviour During Experimental Haemorrhagic Shock

  1992cites this paper
• DDAVP releases tPA in correlation with a fall in platelet serotonin in uraemic patients.

  1992cites this paper
• Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on vasopressin release and blood pressure during hemorrhage.

  1992cites this paper
• Desmopressin Has No Beneficial Effect on Excessive Postoperative Bleeding or Blood Product Requirements Associated with Cardiopulmonary Bypass

  1992cites this paper
• The Influence of Infusions of 1-Desamino-8-D-Arginine Vasopressin (DDAVP) In Vivo on Thrombin Generation In Vitro

  1992cites this paper
• The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro

  1991cites this paper
• Intranasal DDAVP: biological and clinical evaluation in mild factor VIII deficiency.

  1991cites this paper
• Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers.

  1991cites this paper
• DDAVP--the multipotent drug in patients with coagulopathies.

  1991cites this paper
• Pro: desmopressin is of value in the treatment of post-cardiopulmonary bypass bleeding.

  1991cites this paper
• Pro and con

  1991cites this paper
• Pharmacologic agents in the management of bleeding disorders

  1990cites this paper
• Pharmacology and Pharmacokinetics of Desmopressin in Haemostatic Disorders

  1990cites this paper
• Abnormalities of fibrinolytic parameters in patients with myeloproliferative diseases

  1990cites this paper
• Severe thrombotic tendency associated with a type I plasminogen deficiency

  1989cites this paper
• Standardization of methods for measuring plasminogen activator inhibitor activity in human plasma.

  1989cites this paper
• Abnormal fibrinolysis in healthy male cigarette smokers: Role of plasminogen activator inhibitors

  1989cites this paper
• Additive Effect of dDAVP and Standard Heparin inIncreasing Plasma t-PA

  1989cites this paper
• 1-Desamino (8-D-Arginine) Vasopressin (dDAVP) Decreases Blood Pressure and lncreases Pulse Rate in Normal Individuals – Reply

  1989cites this paper
• 1-Desamino[8-D-Arginine]Vasopressin (dDAVP) Decreases Blood Pressure and Increases Pulse Rate in Normal Individuals

  1988cites this paper